PROGEN

High quality & established

Manufacturing antibodies since 1983. DIN EN ISO 13485 Certified and extensively published. All our AAV products are validated by international studies or rigourous internal gold standards.

Easy-to-use tools

Our AAV analytical tools are easy to implement into every workflow. No expensive equipment or special training needed. Products are optimized for a wide range of applications and ready-to-use.

Quick delivery worldwide

Made in Germany. Delivered worldwide. Our off-the-shelf AAV tools can be shipped immediately from Germany or our PROGEN Inc. subsidiary to ensure you get your analytical tools quickly and easily.

On-hand scientific support

We are a team of AAV experts and are partnered with gene therapy experts worldwide. On hand to support you in progressing new AAV gene therapies safely, quickly and affordably.

Find out more

News

Lipid Nanoparticles

With lipid nanoparticles (LNPs), PROGEN offers an alternative drug delivery tool for the gene therapy market.

Read full press release

AAV Dip'n'Check

A quick and easy in-process control for the semi-quantitative detection of fully assembled AAV capsids.

Find out more >

Non-Viral Vectors

How are non-viral vectors changing gene therapy? LNPs are emerging as promising alternatives that could make them integral to the future of gene therapy.

Read full blog post >

"Our experience with PROGEN has been overwhelmingly positive and we are impressed with the lengths that PROGEN go to to make AAV related products successful. The PROGEN team are in constant communication and consultation with us and have exceeded our expectations. An extremely professional, remarkably responsive, and technically proficient team."

Lan Chen, Dakewe

Discover AAV Tools

PROGEN Blog

Science in Action

Meet Head of Research and Development Klaus-Ingmar Pfrepper and find out about his team’s recent discovery of a new AAV antibody.

Overcoming Liver Accumulation: Extrahepatic Targeting Strategies for Lipid Nanoparticles (LNPs)

New targeting strategies are showing how the accumulation of lipid nanoparticles (LNPs) in the liver can be reduced.

Beyond the Virus: How Non-Viral Vectors Are Changing Gene Therapy

Efficient gene delivery is a key challenge in gene therapy. While viral vectors are widely used, lipid nanoparticles (LNPs) are emerging as promising non-viral alternatives.

Five Challenges Of Applying Lipid Nanoparticles As Delivery Tools For Therapeutic Agents

As effective as these delivery vehicles are, they come with their own set of difficulties.

Maximizing Efficiency

Getting a transgene to be expressed inside the target cell is the name of the game.

Bringing New Products to Market

Meet Silja, she is one of our Product Managers here at @PROGEN who is passionate about making sure the team bring you the right tools at the right time to help you go a step further in your AAV gene therapy projects.